Current press releases, talks and reports

Cologne, 02 July 2020 – The paper, published in the journal Cancers, evaluates and discusses the clinical utility of Tumor mutation burden (TMB) in a 417 patient Non-Small Cell Lung Cancer (NSCLC) cohort. It provides an example of how highly complex biomarkers such as TMB can be…

Cologne, 04 June 2020 – In the application note, we discuss the results and findings from a customer project to automate NEOonsite assays using Hamilton’s NGS STAR™ workstation, aiming for a reduction of hands-on time and number of user interventions, while keeping a high level…

Geneva, 13 December 2019 – Tumor mutational burden (TMB) is an emerging complex biomarker that is promising to be predictive for positive response to immunotherapy/checkpoint inhibitor drugs in patients diagnosed with cancer. Different approaches in testing technology made it…

Braunschweig, 01 July 2019 – Braunschweig Municipal Hospital has installed a groundbreaking process for molecular tumor analysis using next-generation sequencing (NGS). We spoke to the hospital’s medical director, Thomas Bartkiewicz, MD, and the head of the Department of…

Hamburg, 08 December 2017 – Markus Tiemann, MD, is the Chief Executive Officer and founder of the Institute for Hematopathology in Hamburg, Germany. During the Annual Meeting of the American Society of Clinical Oncology meeting in June 2017 in Chicago, Dr. Markus Tiemann…